Viking Therapeutics ( (VKTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viking Therapeutics shares are climbing as investors react to renewed optimism around its GLP-1 obesity drug pipeline, led by the VK2735 program now advancing through late-stage clinical trials. The rally also reflects a rebound in sentiment after the company’s recent quarterly earnings and its growing profile in the booming weight-loss treatment market.
Adding fuel to the move, BTIG Research reaffirmed its Buy rating on Viking Therapeutics and kept a $125 price target in place. That target implies the potential for substantial further upside, underscoring Wall Street’s view that the company could unlock significant long-term value if its obesity franchise delivers as expected.
More about Viking Therapeutics
YTD Price Performance: -14.72%
Average Trading Volume: 2,651,338
Technical Sentiment Signal: Hold
Current Market Cap: $3.48B
For further insights into VKTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.